Association of British Clinical Diabetologists

Empagliflozin Nationwide Audit

 
Home Live ABCD audits of new therapies and devices All ABCD nationwide audits Future audits of new therapies ABCD worldwide audits
     

Above - empagliflozin significantly reduced death from cardiovascular causes in the EMPA-REG OUTCOME study - click to see the results from that study
 

Above: the EMPA-REG OUTCOME study showed empaglfliflozin conferred impressive renal protection - click to see the renal results
 

Above - the EMP-REG OUTCOME study triggered a new era with regard to diabetes medications with cardiovascular protection, the subject of some editorials in ABCD's journal, the British Journal of Diabetes. Click here to see one of these editorials
 
 

ABCD nationwide empagliflozin audit on N3

Papers, abstracts, presentations, posters and webcasts emanating from the audit

  

Abstracts
ADA San Fransisco 2019 Ken Thong, Jonathan Chung-Wah-Cheong, Mahender Yadagiri, Melissa L. Cull, Alex Bickerton, Suzanne M. Phillips, Alison Evans, Devesh K. Sennik, Anurita Rohilla, Hazel Reid, David S. Morris, Marc Atkin, Anthony M. Robinson, David M. Williams, Jeffrey W. Stepehens, Ian W. Gallen, Karen Adamson and Robert E. Ryder. Predictors of Glycaemic and Weight Response to Empagliflozin Treatment: The ABCD Nationwide Empagliflozin Audit. Diabetes 2019 Jun; 68 (Supplement 1): 1200-P. https://doi.org/10.2337/db19-1200-P

 

ADA San Fransisco 2019 Ken Thong, Jonathan Chung-Wah-Cheong, Mahender Yadagiri, Melissa L. Cull, Alex Bickerton, Suzanne M. Phillips, Alison Evans, Devesh K. Sennik, Anurita Rohilla, Hazel Reid, David S. Morris, Marc Atkin, Anthony M. Robinson, David M. Williams, Jeffrey W. Stepehens, Ian W. Gallen, Karen Adamson and Robert E. Ryder. Characteristics and Treatment Outcomes of Patients Treated with Empagliflozin in the ABCD Nationwide Empagliflozin Audit. Diabetes 2019 Jun; 68 (Supplement 1): 1201-P. https://doi.org/10.2337/db19-1201-P 

 

Posters

ADA San Francisco June 2019a

ADA San Francisco June 2019b

    Register for the empagliflozin audit: UK

Register simultaneously for ALL 3 SGLT2 audits: canagliflozin, dapagliflozin and empagliflozin

Access the on-line tool
(UK: you need to be on N3)

Empagliflozin audit objectives

Order preprinted data entry forms

Download first visit data entry form

Download follow up visit data entry form

Further information- contact us

Main ABCD homepage

     

The ABCD nationwide empagliflozin audit is an independent audit supported by an unrestricted grant from Boehringer Ingelheim

Working to support high quality diabetes care in the UK